1. Home
  2. QFIN vs TNDM Comparison

QFIN vs TNDM Comparison

Compare QFIN & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Qifu Technology Inc.

QFIN

Qifu Technology Inc.

HOLD

Current Price

$7.33

Market Cap

1.0B

Sector

Finance

ML Signal

HOLD

Logo Tandem Diabetes Care Inc.

TNDM

Tandem Diabetes Care Inc.

HOLD

Current Price

$15.70

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QFIN
TNDM
Founded
2016
2006
Country
China
United States
Employees
N/A
2500
Industry
Finance: Consumer Services
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.1B
IPO Year
2018
2013

Fundamental Metrics

Financial Performance
Metric
QFIN
TNDM
Price
$7.33
$15.70
Analyst Decision
Buy
Buy
Analyst Count
2
19
Target Price
$22.20
★ $28.00
AVG Volume (30 Days)
★ 2.0M
1.7M
Earning Date
05-18-2026
05-07-2026
Dividend Yield
★ 12.36%
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $1,014,736,000.00
Revenue This Year
N/A
$8.11
Revenue Next Year
N/A
$11.85
P/E Ratio
$2.21
★ N/A
Revenue Growth
N/A
★ 7.93
52 Week Low
$7.44
$11.46
52 Week High
$31.08
$29.65

Technical Indicators

Market Signals
Indicator
QFIN
TNDM
Relative Strength Index (RSI) 19.35 34.22
Support Level N/A $14.44
Resistance Level $14.03 $16.50
Average True Range (ATR) 0.26 1.16
MACD 0.05 -0.28
Stochastic Oscillator 0.57 16.67

Price Performance

Historical Comparison
QFIN
TNDM

About QFIN Qifu Technology Inc.

Qfin Holdings Inc is engaged in matching individual borrowers with credit demand to a diversified pool of financial institutions with credit to supply through a financial technology platform. It has released large-scale financial credit multimodal benchmark, building a critical bridge between credit AI research and real-world applications.

About TNDM Tandem Diabetes Care Inc.

Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on the Sigi tubeless patch pump. Tandem is also developing a fully closed-loop algorithm for its pumps. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 3 to 7 days.

Share on Social Networks: